Our Approach

Addressing an Unmet Need
Selectively targets tumor cells with TP53 mutations, which are present in ~70% of aggressive human solid tumors across several cancer types. PHP53-nb killed 80% of triple negative breast cancer cells in a preliminary study.
Strong potential to create a new and enhanced drug by combining the 14 kDa PHP53-nb with other agents like checkpoint inhibitors, cytokines and more.
Innovative Nanobody Platform

About Us
PHP Biotech is a US-based biotech company founded by innovative healthcare entrepreneurs and powered by a world-class scientific team specializing in nanobody and translational biotechnology.
Our lead candidate, PHP53-nb, is a first-in-class humanized nanobody showing strong anti-tumor efficacy, low toxicity, and a novel mechanism of action.
With positive data in triple negative breast cancer models and potential for many other cancer types carrying TP53 mutations there is strong potential as both a stand-alone and add-on therapeutic. The platform can be leveraged for many applications including other oncology targets, immunology and more.

Founder

CEO

COO

Research Leader

Board Member